In this video Dr. Jörg Schüttrumpf, Head of Research & Development, explains very clearly how Biotest can use its new products in the field of coronavirus and what potential they offer for the company.

The Plasma Protein Therapeutics Association, PPTA is of the opinion that the coronavirus is not a problem for the safety of plasma protein therapies.

At Biotest, the safety and well-being of our employees, our customers and the patients who need our products is always our priority. We recognize the important role we play in limiting the spread of the COVID-19 infection and in helping safeguard public health. We are working closely with our customers to ensure the continuity of their businesses and, ultimately, provide stable supplies of medicines to help protect patients’ lives. .

We are in continuous communication with our employees reminding them about the importance of good hygiene, providing them with health education and support whenever needed. We have suspended all international business travel and limited domestic travel to essential meetings only. Wherever feasible, we are transitioning to virtual meetings and providing remote-work solutions. Employees who feel ill have been told to not report to work, likewise if a member of their household has a fever, respiratory condition or flu-like symptoms. Specific quarantine and communication procedures are in place should an employee be diagnosed with COVID-19 or is asked to self-isolate by a public health authority.

To date, we have managed to maintain all of our processes. Of course, this is only a snapshot and there is unfortunately no guarantee that it will stay that way. However, we assure you that Biotest AG will do everything in its power to continue to ensure patient care with life-saving medication.

Please understand that in the current exceptional situation we would like to refrain from replying to individual questionnaires or concerns that you have put forward In case you have further questions, please feel free to contact Biotest’s spokesman Dirk Neumueller, at +49 6103 801-269.

• Biotest AG does not offer any diagnostic Covid-19 tests for sale
   
• The use of the trademark 'Biotest' by Hangzhou Biotest Biotech Co. (HBBCL) in connection with Covid-19 quick tests occurs without our consent
   
• HBBCL is not part of the Biotest or CREAT groups and has no connection to Biotest AG
   
• Biotest AG has initiated measures to defend its trademark rights